Answers are grounded in this paper and cite their sources.
This update highlights strategies to improve transplant outcomes using advanced in silico drug design techniques, suggesting a need for better integration of methods.
In silico approaches already offer a framework to prioritize safer and more selective immunomodulators in SOT. However, integration across omics-based target discovery, CADD, computational repurposing and QSP is still uncommon in this field. Building multidisciplinary consortia and adopting more standardized analytical workflows will be essential to unlock their full translational potential.
No takes yet. Share an insight, caveat, or question.
Alfaro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: